Biological Products, (No Diagnostic Substances)IFRS · EUR

Voyager Acquisition Corp./Cayman Islands

Voyager Acquisition Corp. is a Cayman Islands exempted blank check company formed to complete a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination. It was organized to pursue an initial business combination, with a stated focus on healthcare and healthcare-related businesses, and it operates from executive offices in Brooklyn, New York.

Liikevoitto (EBIT)−1,8milj. EUR
−154,0 %v/v
Nettotulos9,0milj. EUR
+117,1 %v/v
Vapaa kassavirta−0,5milj. EUR
+30,9 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2024–2025

−2,0−1,5−1,0−0,50,0milj. EUR2024: EBIT −0,70 milj. EUR20242025: EBIT −1,8 milj. EUR2025−1,8
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
SPAC formation and capital raising100 %

Issuance of units, ordinary shares, and warrants to raise trust capital for a future acquisition.

Business combination execution0 %

Structuring and completing a merger or similar transaction with a target operating company.

Public listing and sponsor platform0 %

Providing a public-company vehicle and transaction framework for a private target.

Asiakkaat

Voyager does not sell products or services to end customers in the ordinary course; its counterparties are investors in the SPAC and, ultimately, the private company selected as the merger target. The company is designed to identify a business combination candidate, with emphasis on healthcare or healthcare-related businesses, and then provide that target with access to public markets. Its investor base includes public shareholders and private placement participants who fund the trust account and sponsor structure.

Public SPAC investors

Buy units, shares, and warrants for exposure to a future business combination and redemption rights.

Sponsor and private placement investors

Provide capital through sponsor support and warrant purchases to fund the SPAC structure.

Target operating company

A private business that may merge into the SPAC to become publicly listed and access capital markets.

Healthcare and healthcare-related businesses

Preferred target universe for the initial business combination based on management focus.

Strategia

Voyager’s strategy is to identify and complete an initial business combination, with a preference for healthcare and healthcare-related businesses that fit its management team’s network. The company emphasizes proprietary sourcing, alignment with target management, and the ability to help a private business transition into the public markets.

Identify and close an initial business combinationLyhyt aikaväli

The company exists to consummate a merger or similar transaction and create an operating public company.

Source targets through proprietary relationshipsLyhyt aikaväli

A relationship-driven process can improve access to off-market opportunities and reduce auction competition.

Concentrate on healthcare-related targetsKeskipitkä aikaväli

Sector focus helps narrow diligence scope and leverage the team’s background and network.

Maantiede

Voyager is incorporated in the Cayman Islands, while its executive offices are in Brooklyn, New York, and its securities were offered in the United States. The company may pursue a business combination with a target in any geography, but its stated focus is on businesses that fit its management team’s network and healthcare-related sourcing universe. Until a transaction closes, its operations are centered on the U.S. corporate and capital markets framework rather than on operating assets in multiple countries.

Riskit

Voyager’s main risk is execution risk: it must identify, negotiate, and close a suitable business combination before its structure becomes uneconomic or subject to redemption pressure. It also faces competition from other SPACs, private equity firms, and strategic acquirers, plus regulatory and disclosure burdens specific to SPAC transactions and potential investment-company concerns.

Järjestetty vakavuuden mukaan
Failure to complete an initial business combinationKriittinen

The company has no operating revenue and depends on closing a transaction to create value.

Kohdistuu: All shareholders and the sponsor structure

Redemption risk reducing transaction capitalKorkea

Public shareholders may redeem shares, lowering cash available for the merger and post-close operations.

Kohdistuu: Trust account and deal financing

Competition for target businessesKorkea

Other SPACs, private equity groups, and strategic buyers may bid for the same targets.

Kohdistuu: Target sourcing and valuation

SPAC regulatory and disclosure burdenKeskitaso

The 2024 SPAC rules add disclosure, co-registrant, and projection-related requirements.

Kohdistuu: Transaction timing and legal costs

Investment Company Act sensitivityKeskitaso

Duration, asset composition, and activity levels can affect whether SPAC status is challenged.

Kohdistuu: Corporate structure and compliance

Kysy Clarifolta: Voyager Acquisition Corp./Cayman Islands

Kirjanpito

Harkinnanvaraiset erät
Trust account interest income

Interest earned on trust investments is a primary driver of reported non-operating income before a deal closes.

Vaikutus: Affects net income and cash available for taxes or transaction use

Deferred underwriting commission

The fee is payable only upon completion of the initial business combination.

Vaikutus: Creates a contingent transaction cost tied to closing

Warrant and unit accounting

The IPO included units with redeemable warrants, which can require careful classification and valuation.

Vaikutus: Can affect equity presentation and earnings volatility

Redemption and trust-account presentation

Public share redemptions determine how much capital remains for the transaction.

Vaikutus: Impacts liquidity, equity, and deal funding

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Päivitetty: 24.9.2026

Voyager Acquisition Corp./Cayman Islands – Biological Products, (No Diagnostic Subs | Analyysi – Clarifo